A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer
A phase 3 trial testing ASP2138 in gastric & gastro-oesophageal junction cancer, now recruiting.
Overview
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer is a phase 3 interventional study registered as NCT07673887, led by Astellas Pharma Global Development, and recruiting when checked on 2026-09-11. Official title: A Phase 3, Global, Multi-centre, Double-blind, Randomised Study of ASP2138 Plus Chemotherapy (CAPOX or mFOLFOX6) With Pembrolizumab vs Placebo Plus Chemotherapy With or Without Pembrolizumab in First-line Treatment of Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma in Participants Whose Tumours Are HER2-negative and Claudin (CLDN) 18.2-positive. Planned enrolment is 570 participants (estimated). The study started in 2026-06-30 and primary completion is expected in 2031-02-28. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Shares Astellas and the tag ctgov-ingest.
- TrialA Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Shares Astellas and the tag ctgov-ingest.
- TrialA Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialM108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialSymbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialClinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialTo Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.
- TrialA Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shares Gastric & gastro-oesophageal junction cancer and the tag ctgov-ingest.